It’s only fair to share… Imlunestrant CAS 2408840-26-4 as tosylate: 2408840-41-3 (5R)-5-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol MF C29H24F4N2O3 MW 524.516 FDA 9/25/2025, Inluriyo, LY3484356, LY-3484356, To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy Imlunestrant, sold under the brand name Inluriyo, is …